News from eli lilly and company A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 02, 2023, 08:00 ET Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting

New analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in node-positive, high risk early breast cancer show similar efficacy ...

May 30, 2023, 10:00 ET Lilly to Participate in Goldman Sachs Global Healthcare Conference

Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 44th Annual Global Healthcare Conference, June 12-13, 2023. Anat Ashkenazi, Lilly...

May 22, 2023, 10:00 ET Lilly ESG Report Highlights Progress Towards Sustainability Goals

Eli Lilly and Company (NYSE: LLY) today released its latest Environmental, Social and Governance (ESG) report showing progress towards the company's...

May 18, 2023, 06:45 ET Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine

The New England Journal of Medicine today published detailed results from Eli Lilly and Company's (NYSE: LLY) phase 2a study of peresolimab in...

May 11, 2023, 10:00 ET [email protected] Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting

[email protected], the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that data from its oncology portfolio will be presented at the...

May 09, 2023, 09:00 ET Lilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation

Eli Lilly and Company (NYSE: LLY) has allocated an additional $50 million to its now $300 million Social Impact Venture Capital Portfolio, reflecting ...

May 09, 2023, 06:45 ET Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis

Eli Lilly and Company (NYSE: LLY) announced today new investigational data for mirikizumab in patients with moderately to severely active ulcerative...

May 03, 2023, 10:00 ET Lilly to Participate in Bank of America Securities 2023 Healthcare Conference

Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2023 Healthcare Conference, May 9-11, 2023. Patrik Jonsson,...

May 03, 2023, 06:00 ET Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease

Eli Lilly and Company (NYSE: LLY) announced today positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed ...

May 02, 2023, 10:00 ET Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana

To remove barriers and create more equitable, affordable post-high school education opportunities for Indiana's growing immigrant population, Eli...

May 01, 2023, 13:02 ET Lilly Declares Second-Quarter 2023 Dividend

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2023 of $1.13 per share on outstanding...

May 01, 2023, 06:45 ET Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis

New secondary analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 clinical development program showed patients receiving lebrikizumab who were...

Apr 27, 2023, 06:45 ET Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum

Revenue in Q1 2023 decreased 11% driven by a $1.47 billion decline in revenue from COVID-19 antibodies. Excluding COVID-19 antibodies, revenue in Q1...

Apr 27, 2023, 06:15 ET Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2

Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of ...

Apr 24, 2023, 06:45 ET Lilly to Divest BAQSIMI to Amphastar

In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc....

Apr 17, 2023, 11:00 ET Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities

Eli Lilly and Company (NYSE: LLY) announced today that it will invest an additional $1.6 billion and add another 200 new jobs at its two new...

Apr 13, 2023, 16:30 ET U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab

Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the mirikizumab...

Apr 13, 2023, 10:00 ET Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement

Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023. Lilly will also conduct a...

Mar 14, 2023, 16:30 ET Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting

Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the American Association for Cancer...

Mar 08, 2023, 17:00 ET Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease

Eli Lilly and Company (NYSE:LLY) announced today that solanezumab did not slow the progression of cognitive decline due to Alzheimer's disease (AD)...

Mar 08, 2023, 09:00 ET US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes

The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) investigating a...

Mar 06, 2023, 10:30 ET Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study

Providing clinics with a coordinated, multifaceted intervention, with assessment of barriers, care pathways and feedback, improved the likelihood...

Mar 03, 2023, 14:58 ET U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Verzenio®...

Mar 01, 2023, 08:00 ET Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month

Eli Lilly and Company (NYSE: LLY) today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin...

Feb 21, 2023, 10:00 ET Lilly to Participate in Cowen's 43rd Annual Health Care Conference

Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 43rd Annual Health Care Conference on Monday, March 6, 2023. Mike Mason, executive vice ...